Regeneron Reports Third Quarter 2015 Financial and Operating Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. FDX
3. CBRS
4. USO
5. SPY
6. MU
7. KBH
8. HON
9. HTZ
10. GOOGL

Go back to Regeneron Reports Third Quarter 2015 Financial and Operating Results

Leerink Partners Reiterated Outperform Following Regeneron's (REGN) 3Q Beat

November 5, 2015 8:07 AM EST

Leerink Partners reiterated an Outperform rating and $664.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's 3Q earnings report. REGN reported revenues and EPS of $1.14bn and $1.82, respectively, thereby beating consensus estimates of $1.79 and $1.64. REGN tightened its 2015 non-GAAP R&D guidance... More

Regeneron (REGN) Reports Strong Eylea Sales; Cowen Reiterates Market Perform

November 4, 2015 3:55 PM EST

Cowen reiterated a Market Perform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $575.00 (from $550.00), following the company's 3Q15 earnings report. Eylea sales of $734MM were well ahead of consensus of $683MM and 2015 guidance was increased again. Adoption... More

Regeneron (REGN) Tops Q3 EPS by 33c

November 4, 2015 6:31 AM EST

Regeneron (NASDAQ: REGN) reported Q3 EPS of $3.47, $0.33 better than the analyst estimate of $3.14. Revenue for the quarter came in at $1.14 billion versus the consensus estimate of $1.05 billion.

EYLEA® (aflibercept) Injection for Intravitreal Injection

In the third quarter of 2015, net sales of EYLEA in the United States... More